Epilepsy treatment options - PowerPoint Presentation

Slide1

Epilepsy treatment optionsNew, alternative, and experimental

Olgica Laban-Grant, MDNortheast Regional Epilepsy Group

Slide2

Seizures are defined as abnormal discharge of electrical activity of brain resulting in transient impairment of motor, sensory or mental function.Epilepsy: two episodes of unprovoked seizures

Slide3

Epilepsy treatment

Medications

Surgery

Diet

Slide4

New (FDA approved) treatment

Preclinical testing in laboratory animals Clinical Trials - Drug studies in humans can begin only after treatment is reviewed by the FDA and a local institutional review board (IRB). The board is a panel of scientists and non-scientists in hospitals and research institutions that oversees clinical research. 

Slide5

New (FDA approved) treatment

Phase 1 – safety - usually conducted in healthy volunteers. Phase 2 – effectiveness - - usually conducted in patients with certain disease/condition.

Slide6

Clinical trials

Controlled trials - patients receiving the drug are compared with similar patients receiving a different treatment-usually an inactive substance (placebo), or a different drug. Randomized-subjects are randomly allocated to receive one or other of the alternative treatments under study (like tossing a coin)Blinded - both tester and subject are blinded

Slide7

New (FDA approved) treatment

Phase 3 - more information about safety and effectiveness, studying different populations and different dosages and using the drug in combination with other drugs. Post-market requirement and commitment studies

Slide8

Alternative

Any practice that is presented as having the healing effects but is not based on evidence gathered by the scientific method.Complementary medicine is alternative medicine used together with conventional medical treatment (not proven by scientific method)

Slide9

Experimental

Treatments that are still being studied to see if they are effective or safe.Treatment is not part of established treatment practice, or has not yet been subject to extensive clinical studies

Slide10

Experimental

How to find open studies:

http://www.clinicaltrials.gov

http://epilepsygroup.com

Clinical services

open clinical studies

Slide11

Antiepileptic Drugs

Slide12

1850: Bromides1910: Phenobarbital1940: Phenytoin1950: Ethosuximide1968: Carbamazepine1974: Depakote1990s: newer AEDs were developed.Good efficacy,Fewer toxic effects, Better tolerabilityNo blood level monitoring.

Slide13

New Medications

Vimpat (lacosamide) 2008Banzel (rufinamide) 2008Sabril (vigabatrin) 2009Onfi (clobazam) 2011Fycompa (perampanel) 2012

Slide14

Lacosamide (Vimpat)

Approved in 2008Epilepsy treatment for partial-onset seizures in patients who are 17years and older.It is a medication that can be added to any other antiepilepsy medications

Slide15

Lacosamide (Vimpat)

Approximately 40% of patients in clinical studies had their partial-onset seizures reduced by half or more.More seizure-free days

Slide16

Lacosamide (Vimpat)

Mechanism of actionEnhances the number of sodium channels entering into the slow inactivated state       Does not affect activity mediated by fast inactivation

Slide17

Dilantin

Tegretol

Trileptal

Zonegran

Slide18

Vimpat

Slide19

Lacosamide (Vimpat)

Side effectsDepression 1:500Dizziness, double vision, sleepiness, problems with coordinationIrregular heartbeat (may prolong PR interval on EKG)No effect on weightNo effect on memory

Slide20

Banzel (Rufinamide)

Approved in 2008Indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

Slide21

Lennox-Gastaut syndrome

1-4% of childhood epilepsies

Different types of seizures

Mental retardation

Difficult to treat

Specific EEG pattern

Slide22

Banzel (Rufinamide)

reduction in total number of seizures 42.5% median percentage reduction in tonic-atonic seizure(drop attacksignificant improvement in seizure severity

Slide23

Banzel (Rufinamide)

Reports on decrease of frequency of partial seizures –medication is not approved for this indication

Slide24

Banzel (Rufinamide)

The exact mechanism of action is unknown. Modulates the activity of sodium channels and, in particular, prolongation of the inactive state of the channel.

Slide25

Banzel (Rufinamide)

Side effectsDepression 1:500Dizziness, double vision, sleepiness, problems with coordinationMay make the contraception less effectiveIt is contraindicated in familial short QT syndrome-EKG prior to starting it

Slide26

Sabril (Vigabatrin))

Approved in 2009Refractory complex partial seizuresInfantile spasms (IS) - babies between the ages of 1 month and 2 years

Slide27

Infantile spasms

Onset typically 4-8 months

infantile spasms

developmental regression

specific pattern on EEG called hypsarrhythmia (chaotic brain waves)

Slide28

Sabril (Vigabatrin))

Mechanism of actionPreventing breaking down of GABA. GABA is chemical that suppresses activity in neurons.

Slide29

Sabril (Vigabatrin))

Side effectsIt may permanently damage the vision. The most noticeable loss is in the ability to see to the side when looking straight ahead (peripheral vision). Occurred in 30% or more of patient.

Slide30

Ezogabine (Potiga)

FDA approved in 2011Adjunctive therapy in partial-onset seizures uncontrolled by current medications in adults

Slide31

Ezogabine (Potiga)

Novel mechanism of actionPotassium channel opener

Slide32

Ezogabine (Potiga)

Side effectsdizziness, fatigue, tremor, problems with coordination, double visionmemory impairmentlack of strength.urinary retentionconfusion, hallucinationsdepression

Slide33

Ezogabine (Potiga)

New FDA warning in 2013can cause blue skin discoloration and eye abnormalities characterized by pigment changes in the retinaIt is unknown if this is reversiblePatients should have a baseline eye exam and periodic eye exams that should include visual acuity testing

Slide34

Clobazam (Onfi)

FDA approved in 2011Approved for add on treatment for Lennox Gastaut Syndrome.Variable efficacy in partial onset seizures.Mechanism of action: GABA

Slide35

Clobazam (Onfi)

Side effectsCommonsleepinessunsteadinessAggressionDouble visionNausea ,VomitingWithdrawal symptoms on abrupt discontinuation.

Slide36

Perampanel (Fycompa)

Approved in 2012Epilepsy treatment for partial onset seizures in patients with epilepsy ages 12 years and older.

Slide37

Perampanel (Fycompa)

Mechanism of action: selective, non-competitive AMPA receptor antagonist (glutamate receptor)Glutamate is the main excitatory neurotransmitter in the brainnovel mechanism of action

Slide38

Perampanel (Fycompa)

Approximately 19-35% (depending on dose) of patients in clinical studies had their partial-onset seizures reduced by half or more.

Slide39

Perampanel (Fycompa)

Side effectsrisk of serious neuropsychiatric events (including irritability, aggression, anger, anxiety, paranoia, euphoric mood, agitation, and mental status changes.)Common: dizziness, drowsiness, fatigue, irritability, falls, upper respiratory tract infection, weight increase, vertigo, loss of muscle coordination, gait disturbance, balance disorder, anxiety, blurred vision, weakness.

Slide40

Candidate Antiepileptic drugs

Eslicarbazepine (approved in Europe in 2009)prodrug for the major active metabolite of oxcarbazepine (Trileptal)Supposed to be better toleratedBrivarecetamanalog of levetiracetam (Keppra)Supposed to be more potent

Slide41

Candidate Antiepileptic drugs

GanaxoloneNeurosteroid (metabolized from pogesterone), modulation of GABA receptorsGood safety profile

Slide42

Surgical Treatment Options

Surgical

resective

Lobectomy

Hemispherectomy

Corpus

callosotomy

Multiple

subpial

rescections

Surgical

Non-

resective

VNS (Vagal

nerve

stimulator)

Brain stimulators

DBS - Deep Brain Stimulators.

RNS- Responsive

neurostimulator

(

Neuropace

)

r

TMS (

repetitive

transcranial

magnetic

stimulator)

TNS – trigeminal nerve stimulator

Slide43

ExperimentalSurgical Treatment Options

Surgical resection

Focal radiation (gamma knife) vs. temporal

lobectomy

Phase 3

Visualase

Thermal Therapy System -

MR-guided laser induced thermal therapy in patients diagnosed with focal

lesional

epilepsy

Phase 1

Slide44

Other treatments: Devices

DBS - Deep Brain Stimulator

RNS- Responsive

neuro

stimulator (

Neuropace

)

r

TMS - repetitive

transcranial

magnetic stimulator.

TNS – trigeminal nerve stimulator

Slide45

Deep brain stimulator anterior thalamus

Approved in Europe and in Canada.FDA did not approve it in 2010No safety issues – no sufficient time to evaluateBilateral stimulation of the anterior nucleus of the thalamus. New data - 69% median reduction in seizure frequency at 5 years

Slide46

RNS (Neuropace)

It is now being considered for FDA approval. treatment option for patients with bilateral independent seizure foci or with an epileptogenic zone in eloquent cortex not suitable for surgical resection. The generator is implanted in the skull and connected to either depth or subdural strip electrodes to deliver stimulation directly to one or two seizure onset zones. The reduction in seizure frequency was 37.9% in the treatment group compared to 17.3% in the sham stimulation group.

Slide47

rTMS

A noninvasive cortical stimulation methodThe device modulates cortical excitability. Most studies used daily rTMS sessions for about 1 week, then evaluated efficacy 2 to 4 weeks later. Studies show variable results. Relatively more significant improvement was noted in patients who have more superficial seizure foci.

Slide48

Trigeminal Nerve Stimulation

A noninvasive stimulation methodAvailable in EuropePending phase 3 study in USAExternal stimulation of the trigeminal nerve by wearing a gel electrode on the forehead for 12 hours

Slide49

Alternative treatment

Slide50

Dietary Therapy

Possible option in patients with drug resistant epilepsy and epilepsy surgery may not be an option.

Slide51

Dietary Therapy

Ketogenic Diet: Modified Atkins dietLow glycemic diet

Slide52

Ketogenic diet

Very low carbohydrate, high fat, and low to adequate protein diet.The onset of action is very fast. In one study the median time to first improvement was 5 days, with a range of 1 to 65 days. Improvement was unlikely if no benefit had been seen by 2 months.Efficacy of the ketogenic diet in children was confirmed in a randomized controlled but unblinded trial: 38% of children who received the diet had a greater than 50% seizure reduction versus only 6% of controls, 7% had a greater than 90% reduction versus none of the controls .

Slide53

Ketogenic diet

Can be effective All patients with refractory epilepsies.Could be first-line therapy for children with glucose transporter deficiency and pyruvate dehydrogenase deficiency. Myoclonic-astatic epilepsy, tuberous sclerosis, Rett syndrome, Dravet syndrome, and infantile spasms .Absolute contraindications include mitochondrial disorders, pyruvate carboxylase deficiency, and β-oxidation defects.

Slide54

Modified Atkins Diet

It is more palatable and less restrictive than the ketogenic diet. It only restricts carbohydrates (10 g/day for children and 15 g/day for adults), not protein, fat, or calories.In one pediatric study, 65% of children had a greater than 50% reduction in seizures, and In an adult study, 47% had greater than 50% reduction at 3 months and 33% at 6 months, but 33% discontinued the diet before 3 months.

Slide55

Low glycemic diet

The diet allows only low glycemic index carbohydrates, with an overall carbohydrate intake of 40 to 60 g/day. There was a greater than 90% improvement in seizure control in about 25% at 3 months, with another 25% experiencing 50% to 90% improvement. There was a correlation between efficacy and blood glucose at 1 month and 12 months of treatment.

Slide56

Neurofeedback

The theory behind this technique is that patients can be trained to increase certain frequencies on the EEG recordings that are known to inhibit seizures in animal studies.Patients are trained to do this by obtaining positive visual feedback with colored lights and images on a screen after producing the specific activity.

Slide57

Neurofeedback

A therapy that trains patient with realtime feedback on brainwave activity (EEG)EEG is obtained to identify abnormal brain rhythms The patient is trained to change abnormal aspects of brain waves

Slide58

Neurofeedback

Results have not been encouraging although some studies showed improvementPatients who have seizures triggered by anxiety or stressful situations may benefit from this therapy.

Slide59

Herbal treatment

The herbal medicines that are alleged, but not proven, to have a beneficial effect on seizures include:Ailanthus altissima (Tree of Heaven)Artemisia vulgaris (mugwort)Calotropis procera (calotropis)Cannabis sativa (marijuana)Centella asiatica (hydrocotyle)Convallaria majalis (lily of the valley)Dictamnus albus (burning bush)Paeonia officinalis (peony)Scutellaria lateriflora (scullcap)Senecio vulgaris (groundsel)Taxus baccata (yew)Valeriana officinalis (valerian)Viscum album (mistletoe)

Slide60

Herbal treatment

No standardizationingredients do not have to be listedNo scientific studies are requiredNatural is not always safe

Slide61

Herbal “treatment”

May cause seizures: A study conducted with 70 herbal medicines found that 20 % of these products contain potentially harmful levels of neurotoxic materials such as lead, mercury or arsenic that may cause seizures ephedra, gingko, ginseng, evening primrose, borage, and essential oils such as eucalyptus, fennel, hyssop, pennyroyal, rosemary, sage, savin, tansy, thuja, turpentine, and wormwood.May interact with AED’s negatively (reduce effectiveness, increase toxicity)Gingko, St John’s Wort, hankhapusphi, sho-seiryu-to/sho saiko –to and grapefruit

Slide62

Cannabis sativa (marijuana)

naturally growing plant many chemical constituents are present in varying levels in the different varieties. approximately (60 cannabinoids and 260 noncannabinoid)

Slide63

Cannabis sativa (marijuana)

cannabinoid receptors (receptors in the brain for marijuana) are localized in areas that are commonly known to cause seizures (such as the hippocampus and amygdala). There is very little understanding as to what is the effect on seizures.

Slide64

Cannabis sativa (marijuana)

main constituents delta-9-tetrahydrocannibinol (THC), the primary psychoactive constituent, andcannabidiol (CBD) the primary nonpsychoactive constituent.

Slide65

Cannabis sativa (marijuana)

Effect on seizure threshold:THC-conflicting results depending on dose, seizure model, and factors of seizure initiation versus seizure spread CBD- mostly anticonvulsant properties

Slide66

Cannabis sativa (marijuana)

Effect on seizure threshold:3) Cannabidivarin (CBDV) in rats and mice suppressed seizures

Slide67

Cannabis sativa (marijuana)

Case reportsTwo families reported significant improvement in their children with Dravet’s syndrome (rare and catastrophic form of intractable epilepsy)

Slide68

Cannabis sativa (marijuana)

4 studies (by scientific standards of low quality) – total 48 patients200 to 300 mg of cannabidiol (CBD) per day Anti-epileptic drugs were continued in allIn two of the studies, marijuana had no effect on seizure frequency; in one of the studies, 4/8 patients had significant improvement.

Slide69

Cannabis sativa (marijuana)

Small number of patientsUnclear randomizationLimited duration of useNo information on safety/interactions with other medications

Slide70

Cannabis sativa (marijuana)

Risk for the first time seizure – one study (low quality by scientific standards)308 individuals who had been admitted to a hospital after their first seizure vs control group of 294 patients Marijuana within 90 days of hospital admissionconclusion: marijuana is protective against the first-time seizure in men but not women

Slide71

Cannabis sativa (marijuana)

biological product containing multiple compounds with unclear, possible, anti- or pro-convulsant effects, delivered in varying amounts from dose to dose no reliable conclusions can be drawn at present regarding the efficacyvirtually no data about the safety

Slide72

Cannabis sativa (marijuana)

Constituents of marijuana may be treatment optionGW Pharmaceuticals (UK) and Otsuka Pharmaceuticals (Japan) have funded CBD research since 2007 and will continue to until at least 2013

Slide73

Supplements

Folic acid is recommended in women of child baring ageCalcium and vitamin D are recommended in patients taking antiseizure medications.Vitamin B6 is sometimes prescribed with levetiracetam and in B6 sensitive seizures.

Slide74

Supplements

Sometimes mitochondrial disorder may be cause of seizures.Combination of supplements and vitamins may be recommended.

Slide75

Supplements

Vitamin EOne small study (24 participants) found a significant decrease in seizure frequency in those treated with vitamin E compared to placebo.

Slide76

Supplements

Omega 3 fatty acidsA 12-week double blind, placebo-controlled, parallel group trial 50% percent of reduction in complex partial seizures during the first 6 weeks of treatment in both the supplement group (weeks 1-6) but the results were not consistent during the following 6-week periods.

Slide77

Oxygen therapy

Hyperbaric oxygen therapy is approved for treatment of skin ulcers and drowning.Studied in small study with epilepsy patients and revealed decrease in seizures.It is not approved, safety was not established and it might cause seizures even in patients who did not have history of epilepsy.

Slide78

Aromatherapy

Uses aroma to produce relaxationJasmine has been proposed as helpfulSome aromas have been reported to worsen seizures (camphor, eucalyptus, fennel, hyssop, rosemary, sage…)

Slide79

Acupuncture

There have been two trials of an 8 week course of acupuncture versus sham acupuncture in adult patients with intractable epilepsy in addition to their usual AEDs. No significant differences were found between the two groups in either study.Eleven randomized controlled trials. small sample sizes and without any sham or placebo control group. Could not prove whether acupuncture has any beneficiary effects to AEDs

Slide80

Yoga

yoga’s effect on the autonomic functions of patients with refractory epilepsy improved parasympathetic parameters compared to no changes in the non-yoga exercise groupResults on control of seizures are inconclusive

Slide81

Experimental

How to find open studies:

http://www.clinicaltrials.gov

http://epilepsygroup.com

Clinical services

open clinical studies

Slide82

Thank you